UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors

    • Categories

    Archives

    Nov

    20

    Closing gaps in HS care through community engagement and scientific innovation

    Read More Share:linkedin| twitter| email| facebook

    Nov

    20

    UCB Receives U.S. FDA Approval for BIMZELX® (bimekizumab-bkzx) as the First IL-17A and IL-17F Inhibitor for Adults with Moderate-to-Severe Hidradenitis Suppurativa

    Read More Share:linkedin| twitter| email| facebook

    Aug

    16

    UCB Elevates Hidradenitis Suppurativa Awareness with Inaugural Patient and HCP Summit with Special Appearance by Dr. Sandra Lee (AKA "Dr. Pimple Popper")

    Read More Share:linkedin| twitter| email| facebook

    May

    23

    UCB Announces Publication in The Lancet of Phase 3 BIMZELX® (bimekizumab-bkzx) Trials in Moderate-to-Severe Hidradenitis Suppurativa

    Read More Share:linkedin| twitter| email| facebook

    Mar

    08

    BIMZELX® 48-Week Phase 3 Analyses in Moderate-to-Severe Hidradenitis Suppurativa Showed Sustained Improvements in Skin Pain and Draining Tunnel Count

    Read More Share:linkedin| twitter| email| facebook

    Oct

    12

    Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa

    Read More Share:linkedin| twitter| email| facebook

    © 2009 - 2025 UCB, Inc. Atlanta. All rights reserved. 
    Last updated: August 2025